Leukemia - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Treating Multiply Relapsed or Refractory Hairy Cell Leukemia
(Posted: 02/22/2011) - In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine.
Eliminating Hairy Cell Leukemia Minimal Residual Disease
(Posted: 10/19/2010) - In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.
Vaccine Therapy for Patients with Recurrent Blood Cancers
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).
Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.
Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
(Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
(Posted: 02/22/2011) - In this trial, patients with hairy cell leukemia who have not responded to initial chemotherapy followed by second-line treatment with rituximab, or who have relapsed following two courses of chemotherapy, will be randomly assigned to receive rituximab combined with either pentostatin or bendamustine.
Eliminating Hairy Cell Leukemia Minimal Residual Disease
(Posted: 10/19/2010) - In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.
Vaccine Therapy for Patients with Recurrent Blood Cancers
(Posted: 05/04/2010) - In this phase I/II trial, patients with blood cancer that has recurred after allogeneic stem cell transplantation will be treated with donor T-lymphocyte infusions and a dendritic cell vaccine that is designed to trigger an immune response against cells producing a protein called Wilms tumor 1 (WT1).
Extending Targeted Immune Depletion to Unrelated Cord Blood Transplantation
(Posted: 03/09/2010) - In this pilot study, patients with leukemia, lymphoma, multiple myeloma, or certain premalignant blood disorders (such as myelodysplastic syndromes) will undergo targeted immune-depleting chemotherapy followed by unrelated double cord blood transplant.
Studying Immune System Reconstitution Following Unrelated Donor Transplantation and Graft-Versus-Host-Disease Prevention
(Posted: 01/13/2009) - Patients with high-risk, advanced hematologic malignancies will undergo induction chemotherapy, reduced-intensity immune-depleting chemotherapy, and allogeneic stem cell transplantation from a matched, unrelated donor, followed by graft-versus-host disease prevention.
